mRNA vaccines in the context of cancer treatment: from concept to application

Qiang Fu, Xiaoming Zhao, Jinxia Hu, Yang Jiao, Yunfei Yan, Xiaotian Pan, Xin Wang, Fei JiaoJournal of Translational Medicine 2025 · DOI

TL;DR

Building on the momentum of the COVID-19 pandemic, mRNA vaccines are being aggressively pivoted toward oncology as a programmable, high-efficiency immunotherapy platform. This comprehensive review maps the transition of mRNA cancer vaccines from theoretical concepts to clinical applications, highlighting how structural engineering and "Selective Organ Targeting" (SORT) are overcoming historical hurdles like RNA degradation and poor delivery.

What Problem Does This Paper Address?

While immune checkpoint inhibitors (ICIs) have revolutionized cancer care, many patients remain non-responsive due to "cold" tumors that lack sufficient immune infiltration. Traditional cancer vaccines (protein or peptide-based) often suffer from high production costs, limited stability, and weak immunogenicity.

The authors address the technical and biological "bottlenecks" preventing mRNA from becoming a standard oncological tool. Specifically, they explore how to balance the "immunological paradox": the innate immune system must be activated enough to act as an adjuvant, but not so much that it triggers interferon-mediated pathways that degrade the mRNA before it can be translated into therapeutic proteins.

Methods

As a systematic review, this paper synthesizes decades of molecular biology and clinical data. It categorizes the field into four critical engineering domains:

  1. Structural Optimization: Techniques to enhance stability and translation, such as using CleanCap for 99% capping efficiency, modifying UTRs with α/β-globin sequences, and GC-content enrichment in the coding sequence.
  2. mRNA Architectures: A comparison of conventional non-replicating mRNA vs. Self-Amplifying mRNA (SAM), Trans-Amplifying RNA (taRNA), and the highly stable Circular RNA (circRNA).
  3. Delivery Engineering: An evaluation of vehicles ranging from the gold-standard Lipid Nanoparticles (LNPs) to more niche approaches like Exosomes, Polyplexes, and Dendritic Cell (DC) loading.
  4. Target Selection: The strategic choice between Tumor-Associated Antigens (TAAs) (shared across patients but prone to immune tolerance) and Tumor-Specific Antigens (TSAs/Neoantigens) (highly specific and potent but requiring complex, personalized manufacturing).

Datasets

As a review article, the paper does not introduce a new raw dataset. Instead, it aggregates and analyzes:

  • ClinicalTrials.gov Data: Over 100 clinical trials for mRNA vaccines across breast, ovarian, prostate, melanoma, and lung cancers.
  • The Cancer Genome Atlas (TCGA): Referenced to show the correlation between mutational load and the likelihood of forming immunogenic neoantigens.
  • Preclinical Benchmarks: Data from various mouse models evaluating the efficacy of different administration routes (IV, IM, ID, and Intranodal).

Key Insights and Ideas

  • The "Paradox to Equilibrium": The authors highlight that mRNA is its own adjuvant. While this "self-adjuvanticity" is useful, excessive Type I Interferon (IFN) production can actually inhibit the translation of the vaccine itself. Finding the "equilibrium" via nucleoside modification (e.g., using N1-methyl pseudouridine) is the secret sauce of successful mRNA design.
  • Beyond LNPs - The Rise of SORT: A major challenge for IV-delivered LNPs is that they naturally accumulate in the liver. The paper discusses Selective Organ Targeting (SORT), where a "fifth lipid" is added to standard LNPs to change their internal charge, allowing them to bypass the liver and target the lungs or spleen specifically.
  • Programmable Cytokines: mRNA isn't just for antigens. The review emphasizes "mRNA-encoded immunomodulators"—using mRNA to turn the tumor microenvironment (TME) into a "bioreactor" that produces its own IL-12, IL-23, or OX40L to "heat up" cold tumors.
  • Personalization vs. Off-the-Shelf: While neoantigen vaccines (like Moderna’s mRNA-4157) offer the highest specificity, the authors note that "off-the-shelf" TAA cocktails (like BioNTech’s BNT111) remain vital for cancers with low mutational burdens where identifying unique neoantigens is impractical.

Key Results

The paper summarizes the current clinical landscape with several high-profile highlights:

  • Melanoma Success: BioNTech’s BNT111 (targeting four TAAs) and Moderna’s mRNA-4157 (a personalized neoantigen vaccine) have shown significant promise, with mRNA-4157 reaching Phase III trials in combination with Pembrolizumab.
  • Dose Sparing: Self-amplifying mRNA (SAM) was shown in preclinical models to induce protective immune responses at doses 100–1000 times lower than conventional mRNA.
  • Route Matters: Intranodal (IN) injection was found to be significantly more efficient at activating T cells than intradermal (ID) injection because it places the mRNA in direct proximity to high concentrations of resident immune cells.

Limitations and Future Work

The authors identify several "tough challenges" that remain:

  • Tumor Heterogeneity: Cancers evolve. A vaccine targeting a specific neoantigen may fail if a subclone of the tumor lacks that mutation (spatial or temporal heterogeneity).
  • The Immunosuppressive TME: Even a perfectly designed vaccine can be thwarted by the "shield" of the tumor microenvironment. Future work must focus on combining vaccines with ICIs or TME-remodeling agents.
  • Standardization: There is currently no consensus on the "optimal" administration route or the best bioinformatic pipeline for neoantigen prediction, leading to high variability between different manufacturers' results.

The paper concludes that the future of the field lies in collaborative engineering: bridging the gap between molecular biologists designing the RNA and chemical engineers optimizing the delivery vehicles.

Summary updated

Abstract

Immuno-oncology has witnessed remarkable advancements in the past decade, revolutionizing the landscape of cancer therapeutics in an encouraging manner. Among the diverse immunotherapy strategies, mRNA vaccines have ushered in a new era for the therapeutic management of malignant diseases, primarily due to their impressive impact on the COVID-19 pandemic. In this comprehensive review, we offer a systematic overview of mRNA vaccines, focusing on the optimization of structural design, the crucial role of delivery materials, and the administration route. Additionally, we summarize preclinical studies and clinical trials to provide valuable insights into the current status of mRNA vaccines in cancer treatment. Furthermore, we delve into a systematic discussion on the significant challenges facing the current development of mRNA tumor vaccines. These challenges encompass both intrinsic and external factors that are closely intertwined with the successful application of this innovative approach. To pave the way for a more promising future in cancer treatments, a deeper understanding of immunological mechanisms, an increasing number of high-quality clinical trials, and a well-established manufacturing platform are crucial. Collaborative efforts between scientists, clinicians, and industry engineers are essential to achieving these goals.
BibTeX
@article{fu2025mrna,
  author = {Qiang Fu and Xiaoming Zhao and Jinxia Hu and Yang Jiao and Yunfei Yan and Xiaotian Pan and Xin Wang and Fei Jiao},
  title = {{mRNA vaccines in the context of cancer treatment: from concept to application}},
  journal = {Journal of Translational Medicine},
  year = {2025},
  doi = {10.1186/s12967-024-06033-6},
}
Figure